Page 36 - 72_04

BEATRIZ MARTÍNEZ POVEDA Y COLS. AN. R. ACAD. NAC. FARM.

(4) LAGUNA, A. (1570): Pedacio Dioscórides Anazarbeo, acerca de la materia me-
(5) dicinal y de los venenos mortíferos. Salamanca.
TORRES, D. (1727): Cartilla rústica, physica visible y astrología innegable:
(6) lecciones de agricultura y juicios pastoriles para hacer docto al rústico.
(7) Madrid.
(8) BILIA, A. R.; GALLORI, S. and VINCIERI, F. F. (2002): St. John’s wort and depres-
sion: efficacy, safety and tolerability-an update. Life Sci. 70: 3077-3096.
(9) DI CARLO, G.; BORRELLI, F.; ERNST E. and IZZO, A. A. (2001): St John’s wort:
(10) Prozac from the plant kingdom. Trends Pharmacol. Sci. 22: 292-297.
(11) GREESON, J. M.; SANFORD B. and MONTI, D. A. (2001): St. John’s wort (Hype-
(12) ricum perforatum): a review of the current pharmacological, toxicological,
and clinical literature. Psychopharmacol. 153: 402-414.
(13) MULTIPLES AUTORES (2000): European Pharmacopoeia, 3.ª ed., Supp. 2001,
S972. Council of Europe. Strasbourg, Francia.
(14) VITIELLO, B. (1999): Hypericum perforatum extracts as potential antidepres-
sants. J. Pharm. Pharmacol. 51: 513-517.
(15) WOELK, H. (2000): Comparison of St John’s wort and imipramine for treating
depression: randomised controlled trial. BMJ 321: 536-539.
(16) RAFFA, R. B. (1998): Screen of receptor and uptake site activity of hypericin
component of St. John’s wort reveals sigma receptor bonding. Life Sci. 62:
(17) 265-270.
(18) AGOSTINIS, P.; VANTIEGHEM, A.; MERLEVEDE, W. and DE WITTE, P. A. M. (2002):
(19) Hypericin in cancer treatment: more light on the way. Int. J. Biochem. Cell.
Biol. 34: 221-241.
(20) PEEBLES, K. A.; BAKER, R. K.; KURZ, E. U.; SCHNEIDER, B. J. and KROLL, D. J.
(2001): Catalytic inhibition of huuman DBA topoisomerase IIa by hypericin,
a naphthodianthrone from St. John’s wort (Hypericum perforatum). Biochem.
Pharmacol. 62: 1059-1070.
MERUELO, D.; LAVIE, G. and LAVIE, D. (1988): Therapeutic agents with drama-
tic antiretroviral activity and little toxicity at effective doses: aromatic po-
lycyclic diones hypericin and pseudohypericin. Proc. Natl. Acad. Sci. USA 85:
5230-5234.
TANG, J.; COLACINO, J. M.; LARSEN, S. H. and SPITZER, W. (1990): Virucidal
activity of hypericin against enveloped and non-enveloped DNA and RNA
viruses. Antivir. Res. 13: 313-326.
BLANK, M.; MANDEL, M.; HAZAN, S.; KEISARI, Y. and LAVIE, G. (2001): Anti-
cancer activities of hypericin in the dark. Photochem. Photobiol. 74: 120-125.
MALANDRO, M. S. and KILBERG, M. S. (1996): Molecular biology of mammalian
amino acid transporters. Annu. Rev. Biochem. 65: 605-636.
CHATTERJEE, S. S.; BIBER, A. and WEIBEZAHN, C. (2001): Stimulation of glutama-
te, aspartate and gamma-aminobutyric acid release from synaptosomes by
hyperforin. Pharmacopsychiatry 34: S11-S19.
MULLER, W. E.; SINGER, A. and WONNEMANN, M. (2001): Hyperforin-antidepres-
sant activity by a novel mechanism of action. Pharmacopsychiatry 34: S98-
S102.

596